About rasburicas e
Recombinant urate-oxidase enzyme
Used for
- Prevents and treats high uric acid during cancer treatment, especially tumor lysis syndrome.
Usual adult dose
0.2 mg/kg by intravenous infusion once daily for up to 5 days.
Usual dose in children
0.2 mg/kg by intravenous infusion once daily for up to 5 days.
Common side effects
- Allergic reactions, including severe hypersensitivity
- Nausea or vomiting
- Fever
- Headache
Important warnings
- Can cause severe allergic reactions, including anaphylaxis.
- Can cause methemoglobinemia or hemolysis, especially with glucose-6-phosphate dehydrogenase deficiency.
- Do not use in known G6PD deficiency.
- Blood samples for uric acid need special handling and rapid cooling.
Pregnancy
Limited information; use only when clearly needed after weighing potential risks and benefits.
Breastfeeding
Unknown whether it passes into breast milk; breastfeeding decisions should consider treatment necessity and infant exposure.
Interactions
- Rasburicase breaks down uric acid, which can interfere with uric-acid test results.
- Other medicines affecting blood-cell breakdown may increase concern for hemolysis.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.